BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 266,690 Shares of Catalent, Inc. (NYSE:CTLT)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its stake in Catalent, Inc. (NYSE:CTLT - Free Report) by 31.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 575,446 shares of the company's stock after selling 266,690 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.32% of Catalent worth $34,855,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent in the second quarter valued at $42,000. Sentry Investment Management LLC bought a new stake in Catalent in the 3rd quarter valued at about $53,000. Longfellow Investment Management Co. LLC boosted its stake in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock valued at $55,000 after purchasing an additional 305 shares during the period. GAMMA Investing LLC boosted its stake in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock valued at $58,000 after purchasing an additional 212 shares during the period. Finally, Intact Investment Management Inc. acquired a new position in Catalent during the 3rd quarter valued at about $73,000.

Catalent Trading Up 2.2 %

Shares of CTLT traded up $1.32 during midday trading on Friday, hitting $60.98. The stock had a trading volume of 4,869,610 shares, compared to its average volume of 1,753,712. The business has a 50-day simple moving average of $59.81 and a two-hundred day simple moving average of $58.29. The firm has a market cap of $11.07 billion, a P/E ratio of -26.98, a price-to-earnings-growth ratio of 2.37 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50.

Catalent (NYSE:CTLT - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.10) earnings per share. As a group, equities analysts forecast that Catalent, Inc. will post 0.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CTLT. StockNews.com lowered shares of Catalent from a "hold" rating to a "sell" rating in a research note on Friday. Robert W. Baird reiterated a "neutral" rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Baird R W lowered Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Finally, William Blair reissued a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $63.40.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the firm's stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company's stock, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 over the last three months. 0.31% of the stock is owned by corporate insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.